- Home
- HBT vs PRAX Comparison
HBT vs PRAX Comparison
Compare HBT & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBT
- PRAX
- Stock Information
- Founded
- HBT 1920
- PRAX 2015
- Country
- HBT United States
- PRAX United States
- Employees
- HBT N/A
- PRAX N/A
- Industry
- HBT Major Banks
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- HBT Finance
- PRAX Health Care
- Exchange
- HBT Nasdaq
- PRAX Nasdaq
- Market Cap
- HBT 812.0M
- PRAX 950.8M
- IPO Year
- HBT 2019
- PRAX 2020
- Fundamental
- Price
- HBT $25.80
- PRAX $44.03
- Analyst Decision
- HBT Buy
- PRAX Strong Buy
- Analyst Count
- HBT 5
- PRAX 9
- Target Price
- HBT $29.00
- PRAX $94.44
- AVG Volume (30 Days)
- HBT 22.3K
- PRAX 383.5K
- Earning Date
- HBT 10-20-2025
- PRAX 11-05-2025
- Dividend Yield
- HBT 3.32%
- PRAX N/A
- EPS Growth
- HBT 8.10
- PRAX N/A
- EPS
- HBT 2.42
- PRAX N/A
- Revenue
- HBT $229,851,000.00
- PRAX $7,765,000.00
- Revenue This Year
- HBT $8.86
- PRAX N/A
- Revenue Next Year
- HBT $2.52
- PRAX $22.22
- P/E Ratio
- HBT $10.46
- PRAX N/A
- Revenue Growth
- HBT 4.61
- PRAX 338.45
- 52 Week Low
- HBT $19.46
- PRAX $26.70
- 52 Week High
- HBT $27.02
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- HBT 50.84
- PRAX 48.77
- Support Level
- HBT $24.49
- PRAX $37.25
- Resistance Level
- HBT $26.43
- PRAX $40.69
- Average True Range (ATR)
- HBT 0.62
- PRAX 2.54
- MACD
- HBT -0.11
- PRAX -0.03
- Stochastic Oscillator
- HBT 51.84
- PRAX 61.04
About HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.